Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301



Status:Recruiting
Conditions:Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:3/22/2019
Start Date:June 18, 2018
End Date:July 2020
Contact:Douglas Wight
Email:dwight@milestonepharma.com
Phone:+1-514-336-0444

Use our guide to learn which trials are right for you!

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.

The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg
is superior to placebo at terminating episodes of PSVT in an outpatient setting.

NODE-301 is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate
the efficacy and safety of a nasal spray of etripamil, a new calcium channel blocker, in
patients who experience an episode of paroxysmal ventricular tachycardia (PSVT).

The study includes a Screening Visit during which prospective study patients suffering
episodes of PSVT will sign the informed consent form. All patients will receive a test dose
of etripamil nasal spray 70 mg to evaluate the tolerability of etripamil under medical
supervision including continuous ECG. A patient will be randomized only if the test dose is
well tolerated.

All the randomized patients will be trained to recognize the symptoms of PSVT, perform a
vagal maneuver, and self-administer the nasal spray study drug to terminate the episode of
PSVT. The patient will place an ambulatory cardiac monitoring system (CMS) on the chest at
the onset of symptoms to record at least 5 hours of continuous ECG and document the
tachycardia and its termination. A Final Study Visit will occur at the study site within 7
days after the episode to evaluate the clinical effects of the study drug and to review the
report of the CMS data.

Follow-up Visits will occur approximately monthly from the time of randomization and will be
conducted in person at the site or by telephone.

Inclusion Criteria:

1. Male or female patients at least 18 years of age

2. Electrographically documented history of PSVT (e.g., ECG obtained during an episode of
PSVT, Holter monitoring, or loop recorder, etc.)

3. History of sustained episodes of PSVT (i.e., typically lasting approximately 20
minutes or longer)

4. Females of childbearing potential must agree to use an approved highly effective form
of contraception from the time of signed informed consent until 30 days after the last
administration of study drug and should have a negative serum pregnancy test result at
the Screening Visit, a negative urine pregnancy test at the Test Dose Randomization
Visit and must use an approved form of contraception between the 2 visits. Approved
forms of contraception include hormonal intrauterine devices, hormonal contraceptives
(oral birth control pills, Depo-Provera®, patch, or other injectables) together with
supplementary double-barrier methods, such as condoms or diaphragms with spermicidal
gel or foam.

The following categories define females who are NOT considered to be of childbearing
potential:

- Premenopausal females with 1 of the following:

1. Documented hysterectomy,

2. Documented bilateral salpingectomy, or

3. Documented bilateral oophorectomy, or

- Postmenopausal females, defined as having amenorrhea for at least 12 months
without an alternative medical cause;

5. Males, except those who are surgically sterile, must use an approved highly effective
form of contraception during the 3 days after any study drug administration; and

6. Signed written informed consent.

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded from participation in the
study:

1. Systolic blood pressure <90 mmHg after a 5-minute rest in sitting position at the
Screening Visit or before the test dose. In patients treated with a chronic
prophylactic drug for PSVT (e.g., beta-blockers, verapamil, and diltiazem), the drug
may be stopped for at least the equivalent of 5 half-lives and patients may be
rescreened once

2. History of severe symptoms of hypotension, especially syncope, during episodes of PSVT

3. History of atrial arrhythmia that does not involve the AV node as part of the
tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial
tachycardia)

4. History of allergic reaction to verapamil

5. Current therapy with digoxin or any Class I or III antiarrhythmic drug, except if
these drugs are stopped at least the equivalent of 5 half-lives before the Test Dose
Randomization Visit

6. Current therapy with amiodarone, or have taken amiodarone within 30 days prior to the
Test Dose Randomization Visit

7. Evidence of ventricular pre-excitation (e.g., delta waves, short PR interval <100
msec, Wolff-Parkinson-White syndrome) on the ECG performed at the Screening Visit or
before the test dose administration

8. Evidence of a second- or third-degree AV block on the ECG performed at the Screening
Visit or before the test dose administration

9. History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes,
ventricular fibrillation, or sustained ventricular tachycardia)

10. Current congestive heart failure defined by the New York Heart Association Class II to
IV

11. Stroke in the last 6 months

12. Evidence of hepatic dysfunction defined as alanine aminotransferase or aspartate
aminotransferase >3 × the upper limit of normal (ULN) or total bilirubin >2 × ULN at
the Screening Visit, unless due to Gilbert syndrome;

13. Evidence of renal dysfunction as determined by an estimated glomerular filtration rate
assessed at the Screening Visit as follows:

1. <60 mL/min/1.73 m2 for patients <60 years of age;

2. <40 mL/min/1.73 m2 for patients ≥60 and <70 years of age; or

3. <35 mL/min/1.73 m2 for patients ≥70 years of age;

14. Evidence or history of any significant physical or psychiatric condition including
drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of
patients, or affect their participation in the study. Additionally, the Investigator
has the ability to exclude a patient if for any reason the Investigator judges the
patient is not a good candidate for the study or will not be able to follow study
procedures

15. Current participation in any investigational drug or device study or the use of any
investigational drug or device within 30 days of the Screening Visit.

Before randomization, all patients will receive a test dose of etripamil NS 70 mg to
evaluate tolerability and to train patients for the procedures. A failure of the test dose
is considered if patients meet any of the following criteria occurring after administration
of the etripamil NS 70 mg test dose:

1. Any symptoms consistent with clinically severe hypotension such as pre-syncope,
medically significant lightheadedness, syncope, nausea, or vomiting;

2. For patients with a pre-test dose Systolic Blood Pressure above 100 mmHg:

1. Decrease in SBP ≥40 mmHg after test dose; or

2. Post-test dose SBP <80 mmHg;

3. For patients with a pre-test dose SBP between 90 mmHg and 100 mmHg (inclusive):

a) Post-test dose SBP <75 mmHg;

4. Third-degree AV block, Mobitz II second-degree AV block, or Wenckebach with
bradycardia ≤40 bpm;

5. New, significant sinus bradycardia Heart Rate ≤40 bpm or sinus pauses (≤3 seconds), if
considered by the Investigator to put the patient's safety at risk if either were to
occur while not under medical supervision;

6. Any significant ventricular arrhythmia (premature ventricular beats and couplets [>6
premature ventricular contractions per 45 seconds ECG] are considered significant);
and

7. Atrial fibrillation (event lasting longer than 30 seconds).

Patients who fail the test dose will proceed in the study as follows:

- If the Investigator identifies a possible reversible cause of the initial test dose
failure (e.g., concomitant medication such as beta-blocker), a re-challenge with a new
test dose of etripamil NS 70 mg will be possible after elimination of the reversible
cause (e.g., withdrawal of concomitant therapy with the appropriate washout period).
Patients may be randomized if they pass the second test dose and the cause of the test
dose failure is eliminated for the duration of the study; or

- If the Investigator cannot identify a reversible cause of the initial test dose
failure, or if the potential cause cannot be modified (e.g., necessary
antihypertensive drug to control blood pressure), patients will not be randomized and
will complete a Final Study Visit. Patients who fail the test dose will be part of the
Test Dose Population, including all patients who received at least 1 test dose of
etripamil NS 70 mg
We found this trial at
49
sites
Jacksonville, Florida 32216
Principal Investigator: K.L. Venkatachalam, Dr.
Phone: 904-953-8268
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
1200 Moursund Street
Houston, Texas 77030
(713) 798-4951
Principal Investigator: Wilson Lam, Dr.
Phone: 731-798-1037
Baylor College of Medicine Baylor College of Medicine in Houston, the only private medical school...
?
mi
from
Houston, TX
Click here to add this to my saved trials
4085 University Blvd S # 1
Jacksonville, Florida 32216
Principal Investigator: Michael Koren, Dr.
Phone: 904-732-6674
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Sean Mazer, Dr.
Phone: 505-843-2827
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Annapolis, Maryland 21401
Principal Investigator: Michael Goldstein, Dr.
Phone: 240-444-5829
?
mi
from
Annapolis, MD
Click here to add this to my saved trials
Apex, North Carolina 27502
Principal Investigator: Srivani Ambati, Dr.
Phone: 919-363-6060
?
mi
from
Apex, NC
Click here to add this to my saved trials
Atlanta, Georgia 30309
Principal Investigator: Bruce Stambler, Dr.
Phone: 404-605-2875
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Baltimore, Maryland 21237
Principal Investigator: Glenn Meininger, Dr.
Phone: 443-777-2369
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boise, Idaho 83712
Principal Investigator: Marcos Daccarett, Dr.
Phone: 203-388-7216
?
mi
from
Boise, ID
Click here to add this to my saved trials
3050 Orchard Park Road
Buffalo, New York 14215
Principal Investigator: Robert Gianfagna, Dr.
Phone: 716-835-2966
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
Calgary, Alberta
Principal Investigator: Stephen Wilton, Dr.
Phone: 403-220-2217
?
mi
from
Calgary,
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Thomas Kambur, Dr.
Phone: 704-264-1400
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chicago, Illinois 60608
Principal Investigator: Sandeep Khosla, Dr.
Phone: 872-222-7830
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Gaurang Gandhi, Dr.
Phone: 513-862-2877
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Columbus, Georgia 31904
Principal Investigator: Jones Sr. Alonzo, Dr.
Phone: 706-321-0495
?
mi
from
Columbus, GA
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Ralph Augostini, Dr.
Phone: 614-685-4624
?
mi
from
Columbus, OH
Click here to add this to my saved trials
11108 Parkview Plaza Drive
Fort Wayne, Indiana 46845
Principal Investigator: David Schleinkofer, Dr.
Phone: 260-266-6628
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Fort Worth, Texas 83702
Principal Investigator: Vijay J. Jayachandran, Dr.
Phone: 943-433-1085
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Gurnee, Illinois 60031
Principal Investigator: Isaac Dor, Dr.
Phone: 847-599-2492
?
mi
from
Gurnee, IL
Click here to add this to my saved trials
Indianapolis, Indiana 46237
Principal Investigator: Robert Kinn, Dr.
Phone: 317-893-1712
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Christopher Ruisi, Dr.
Phone: 904-202-7218
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lansing, Michigan 48912
Principal Investigator: John Ip, Dr.
Phone: 517-364-5737
?
mi
from
Lansing, MI
Click here to add this to my saved trials
254 West 2675 North
Layton, Utah 84041
Principal Investigator: Sandeep Talwar, Dr.
Phone: 801-928-3292
?
mi
from
Layton, UT
Click here to add this to my saved trials
Little Rock, Arkansas 72205
Principal Investigator: Greer Gerald, Dr.
Phone: 501-227-7596
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Littleton, Colorado 80120
Principal Investigator: Roger Damle, Dr.
Phone: 303-703-2191
?
mi
from
Littleton, CO
Click here to add this to my saved trials
Los Alamitos, California 90720
Principal Investigator: Ramandeep Brar, Dr.
Phone: 562-430-7533
?
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
Lynchburg, Virginia 24501
Principal Investigator: Richard Kuk, Dr.
Phone: 434-200-2727
?
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Macon, Georgia 31201
Principal Investigator: Felix Sogade, Dr.
Phone: 478-755-1560
?
mi
from
Macon, GA
Click here to add this to my saved trials
Macon, Georgia 31201
Principal Investigator: Sean Beinart, Dr
Phone: 301-891-5612
?
mi
from
Macon, GA
Click here to add this to my saved trials
Miami, Florida 33125
Principal Investigator: Luis Ortiz Munoz, Dr.
Phone: 786-452-1644
?
mi
from
Miami, FL
Click here to add this to my saved trials
Murray, Utah 84157
Principal Investigator: Jeffrey Anderson, Dr.
Phone: 801-507-4760
?
mi
from
Murray, UT
Click here to add this to my saved trials
New Smyrna Beach, Florida 32169
Principal Investigator: Erick Lo, Dr.
Phone: 386-426-7938
?
mi
from
New Smyrna Beach, FL
Click here to add this to my saved trials
New York, New York 10065
Principal Investigator: James Ip, Dr.
Phone: 212-746-4617
?
mi
from
New York, NY
Click here to add this to my saved trials
Norfolk, Virginia 23507
Principal Investigator: Robert Bernstein, Dr.
Phone: 757-388-4024
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
Overland Park, Kansas 66215
Principal Investigator: Dhanunjaya Lakkireddy, Dr.
Phone: 816-651-1969
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
Phoenix, Arizona 85006
Principal Investigator: Vijendra Swarup, Dr.
Phone: 602-456-2342
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Port Charlotte, Florida 33952
Principal Investigator: Sergio Cossu, Dr.
Phone: 941-613-0330
?
mi
from
Port Charlotte, FL
Click here to add this to my saved trials
Potsdam, New York 13676
Principal Investigator: Alexandru Stoian, Dr.
Phone: 315-261-5611
?
mi
from
Potsdam, NY
Click here to add this to my saved trials
Richmond, Virginia 23298
Principal Investigator: Kenneth Ellenbogen, Dr.
Phone: 804-828-4700
?
mi
from
Richmond, VA
Click here to add this to my saved trials
223 N Van Dien Ave
Ridgewood, New Jersey 07450
(201) 447-8000
Principal Investigator: Suneet Mittal, Dr.
Phone: 201-447-8000
The Valley Hospital The Valley Hospital is a fully accredited, acute care, not-for-profit hospital serving...
?
mi
from
Ridgewood, NJ
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Peter Noseworthy, Dr.
Phone: 507-255-6676
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95819
Principal Investigator: Gearoid O'Neil, Dr.
Phone: 919-453-2626
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Springfield, Ohio 45505
Principal Investigator: Pradeep Gujja, Dr.
Phone: 937-323-1404
?
mi
from
Springfield, OH
Click here to add this to my saved trials
Temple, Texas 76508
Principal Investigator: Greg Olsovsky, Dr.
Phone: 254-724-1392
?
mi
from
Temple, TX
Click here to add this to my saved trials
Toledo, Ohio 43606
Principal Investigator: Johan Aasbo, Dr.
Phone: 419-842-3025
?
mi
from
Toledo, OH
Click here to add this to my saved trials
Visalia, California 93291
Principal Investigator: Aditya Verma, Dr.
Phone: 559-578-4062
?
mi
from
Visalia, CA
Click here to add this to my saved trials
Wausau, Wisconsin 54401
Principal Investigator: Kevin Rist, Dr.
Phone: 715-847-2273
?
mi
from
Wausau, WI
Click here to add this to my saved trials
West Des Moines, Iowa 50266
Principal Investigator: Denise Sorrentino, Dr.
Phone: 515-633-3843
?
mi
from
West Des Moines, IA
Click here to add this to my saved trials
Willoughby, Ohio 44094
Principal Investigator: Robert Goldstein, Dr.
Phone: 440-667-6301
?
mi
from
Willoughby, OH
Click here to add this to my saved trials